Connect with us

Advocacy

“It’s been a real game-changer” – Patients speak on the benefits of medical cannabis

The panel was part of Medical Cannabis Awareness Week, which runs from 1-7 November.

Published

on

Patients: A collection of brown bottles containing CBD oil, cannabis and a green cannabis leaf on a wooden surface

Patients spoke about the side effects of prescription drugs and the improvement in their quality of life since starting cannabis-based medicines, as part of Medical Cannabis Awareness Week.

The panel was organised by the patient advocacy group, PLEA (Patient-Led Engagement for Access) as part of Medical Cannabis Awareness Week which runs from 1-7 November to acknowledge that it has been three years since the legalisation of medical cannabis.

The discussion on the different conditions that cannabis may help included patients and doctors. The wide variety of conditions included Attention Deficit Hyperactive Disorder (ADHD), endometriosis, anxiety, Autism Spectrum Disorder (ASD), Parkinson’s Disease, fibromyalgia among others.

The panel, led by David Johnston from PLEA’s patient working group, included fellow members Jack Pierce, Noel Brown and Kayleigh Ross. They were joined by Laura, the founder of the blog, The Endo Monologues and Dr Wendy Holden, a pain specialist.

Patients and side effects.

The panel began with a group discussion on the different conditions and medications that the patients had been prescribed. As cannabis is often the last medication prescribed for most conditions, they had all experienced a variety of drugs including opioids.

Laura, who chose to remain anonymous due to her position as a teacher, had experienced debilitating pain which has left her bedridden around the time of her period due to endometriosis. She described the clarity she experienced from cannabis and described it as a ‘game-changer.’

She said: “I’ve been a medical cannabis user for six months but during that, I’m now completely off all pharmaceutical drugs. A lot of my endometriosis pain sits in my sciatic nerve so it will travel down to my legs but I’m at a point now where I just have to use medical cannabis and that is sufficient to manage my pain.

READ MORE  Seeding the future

“I’m not continuously in a medication haze and I’m actually very clear as I have clarity. It’s had a knock-on effect on my other conditions too, I suffer from obsessive-compulsive disorder (OCD) so that seems to have settled now because of the cannabis. For me, it’s been a real game-changer.”

Patients: A collection of CBD bottles and cannabis leaves on a white background

Jack also explained the irony of being prescribed stimulant medications for ADHD which can often have dangerous side effects before being given cannabis-based medications. He also highlighted that his other conditions could sometimes be triggered by stimulant-based medications such as anxiety.

“The standard treatment for my conditions that I’ve tried revolved around therapies and medications. As a result of the multiple conditions, anxiety, ASH, ADHD, the medications have always been SSRI inhibitors and now, prescribed amphetamines. I’ve had a series of adverse effects to all of the mental health medications in the past which is perhaps why I went undiagnosed for autism and ADHD for so long because the medications were not suitable for those conditions,” he said.

“They often left me really withdrawn, having night terrors, stomach upsets and I couldn’t function at all. The Elevanse that I’m now prescribed, which is prescribed amphetamines for ADHD is beneficial in some areas but comes with a load of risks to my health. I’m not sure how long I want to endure those risks.”

Jack said he had been on Elevanse for two weeks before doctors wanted to increase the dose he was taking. “I’m a person who has never used prescribed amphetamines. Why do I, within two weeks of being prescribed it, have to jump up?”

READ MORE  ‘Crisis’ in paediatric access to medical cannabis forcing parents to black market

Kayleigh Ross agreed with Jack that for her, it was easier to get opiate-based medications. She also acknowledged the role the pandemic had in introducing telemedicine.

She said: “It’s the same issue with opiate-based medications as I can easily go to the GP and get some form of opiate-based medication but to be able to be prescribed medical cannabis, you’ve got to jump through so many hoops. If I go to the doctor now, I could get given morphine which I don’t want because it’s addictive. The barriers to access are a huge issue.”

Patient locations

She added that her rural location of an island in Scotland made access even harder. “The clinics are all in England. I live on an island and it costs hundreds of pounds to get off the island, let alone travelling the whole length of the UK to get down to England. It costs a lot of money and it would never have been possible if it wasn’t for the pandemic and Project Twenty21 for subsidising costs.”

Host, David Johnston also touched on how telemedicine had meant he could switch to medical cannabis to help manage his conditions which include fibromyalgia and ASD. He is also based in Scotland.

“The barriers to access is a huge issue. It’s quite ironic, but if it hadn’t been for the pandemic and the growth of telemedicine then I am not sure if I’d ever have been able to approach it and become a patient.”

The panel also touched on the issue of the police and safety while travelling with their medication.

READ MORE  Is cannabis a girl’s new best friend?

Jack spoke about the worry of having cannabis-based medications while travelling. Patients are advised to leave their medication in the original container from the pharmacy as further proof of their prescription. This may mean that if a patient is stopped, they risk having all, not some, of their medication, seized.

“I worry about taking my medications anywhere in case I get stopped,” he said. “I am told I have to keep all my medication in its original packaging with all of it in there. That is a considerable amount of cannabis to be having on me. It doesn’t look like a good scenario. It’s constantly at the back of my mind.

Patient quality of life

Kayleigh explained that in comparison to pharmaceuticals, medical cannabis had a positive effect on her life. “You might get a little bit more sleep or eat more but to me, because I’ve had an eating disorder, eating more is a good thing.”

David said that for him, medical cannabis had cleared the brain fog often associated with fibromyalgia. “For me personally, it cleared up brain fog. I’m actually more clear-headed after I’m able to medicate.

Jack elaborated on brain fog and ADHD. “With ADHD, the head just gets so rushed with so many thoughts that you can’t pick them out so it gets so confusing and overwhelming. When you medicate, they just fall into place and you can focus on one. It gives you that structure again otherwise it gets completely too much and overwhelming for any person.”

Advocacy

US Congresswoman speaks out about how cannabis helped her depression

Nancy Mace spoke out about using cannabis to help her depression after experiencing a traumatic event as a teenager

Published

on

Image credit: Nancy Mace/Instagram

A Republican congresswoman who has proposed a federal bill to legalise cannabis has spoken out about her experience using cannabis to combat depression.

Nancy Mace, a republican politician from South Carolina appeared on Fox Business’s ‘Kennedy’ show to talk about the bill which would legalise cannabis but would also focus on veteran access.

It also includes expungement for non-violent cannabis crimes and imposes a revenue tax that would support reinvestment into communities hurt by the war on drugs.

Bill: A banner for always pure organics

The bill titled the States Reform Act would federally legalise and tax cannabis has been proposed ahead of competing Democrat proposed bills. While the bill was originally proposed in July, Mace shared her story after officially filing the State Reform Act in November.

At the end of the discussion, host, Lisa “Kennedy” Montgomery asked the congresswoman if she smoked cannabis.

Nancy replied: “When I was 16, I was raped. I was given prescription medication that made the feelings I had of depression worsen, and I stopped taking those prescription drugs and I turned to cannabis for a brief period of time in my life.”

She added that she believed her experience with cannabis made her more sympathetic to veterans who may use cannabis for conditions such as post-traumatic stress disorder (PTSD).

Bill protection for veterans

The congresswoman explained that the new bill is “particularity protective of veterans, ensuring they are protected, not discriminated against and that the US Department of Veteran Affairs can utilise cannabis for their PTSD.”

READ MORE  Sexual Health Awareness week: Could CBD help with sex?

She added: “When I talk to vets and I see that pain, it hurts because I felt that pain before in my life. Veteran suicide, we see every single day.”

One other provision in the bill is that cannabis would be under the Treasury Department’s Alcohol and Tobacco Tax and Trade Bureau (TTB) instead of the Food and Drug Administration (FDA). The FDA would have some involvement similar to its current control over the alcohol industry.

Bill history

Mace has already won an exception for rape and incest victims in a fatal fetal heartbeat bill. She mentioned her history when it came to proposing that bill in 2019.

She said: “I’ve had family that have overdosed from hardcore opiates and prescription drugs. And I’ve mentioned part of this in 2019, at the time I got the exception for rape and incest in the fetal-heartbeat bill I told my story about being raped when I was 16, but I’ve never said this part publicly before: I was prescribed antidepressants afterwards, and it made my feelings a lot worse. And so I started using cannabis for a brief moment, for a time in my life. It helped me. It cut down on my anxiety and helped me get through some dark periods.”

 

Fibromyalgia: A banner advert for cannabis health news

Continue Reading

Advocacy

First patient set to receive cannabis products on Ireland’s MCAP programme

CannEpil is the first drug available through the programme but has yet to be prescribed

Published

on

Ireland HSE offer medical cannabis
CannEpil was announced as the first drug to be made available through the programme

Earlier this year, the Irish Health Service Executive (HSE) has announced that the first cannabis-based products will be available through the Medical Cannabis Access Programme from mid-October.

Despite an update from the Irish health service (HSE) and Health Products Regulatory Authority (HPRA) that CannEpil would be prescribed by the middle of October, the first prescription has been delayed.

People before Profit TD for Dublin Mid-West Gino Kenny tweeted that the first prescription should be available from next week.

The HSE has yet to confirm that the products will be available from next week but says they would not be aware until the consultant neurologist has issued claims at the end of the month.

In a statement to Cannabis Health News, a press officer at the HSE stated: “The HSE has registered three patients under the MCAP in recent days. We would not be aware whether the consultant neurologist has proceeded with prescribing for an individual until claims were submitted from pharmacies at the end of the month.”

He also raised the issue in the Dáil earlier this month to Taoiseach, Michael Martin.

“Many families would have been very joyous during the summer when the medical cannabis access programme was to commence. But sadly, in a PQ response today, not one patient has been given access thus far. That is a huge disappointment to those families that this treatment could make life-changing benefits,” he said.

READ MORE  ‘Crisis’ in paediatric access to medical cannabis forcing parents to black market

“So what do you say to families that feel let down by the program and now they have to look at other treatments and probably getting no treatment at all?” He asked.

Michael Martin replied that a lot of patients have been facilitated by the original ‘imported license’ but he was unsure as to why patients had not availed of the MCAP. He promised to follow up with the Minister for Health, Stephen Donnelly of Fianna Fáil.

Gino announced changes to the Cannabis Regulation and Control bill that he is due to submit. It will now take place next year with a focus on production and consumption for personal use.

HSE committee meeting

In a joint committee meeting held in September, CannEpil was announced as the first drug to be made available through the program from mid-October.

Ireland’s Health minister Stephen Donnelly announced funding for the Medical Cannabis Access Programme (MCAP) in January, almost two years since the legislation was signed off in June 2019.

The programme will offer access to cannabis-based medicines to people living with one of three qualifying conditions. These include intractable nausea and vomiting associated with chemotherapy, severe treatment-resistant epilepsy and spasticity associated with multiple sclerosis (MS) where patients have failed to respond to authorised treatments.

The meeting saw officials from the Department of Health and the Health Products Regulatory Authority (HPRA) outline the current state of the MCAP programme and the Ministerial License system.

READ MORE  CBDiablo donates 20% of profits to suicide prevention

The suppliers of two products, CannEpil and Tilray are said to have confirmed their prices to the HSE, but Tilray has yet to announce its availability date.  Two more cannabis-based products have been added to the schedule but suppliers are not thought to have current plans to supply the Irish market.

Morris O’Connor, the assistant national director of primary care reimbursement, announced that two additional products were expected to be added to the schedule in the coming weeks and that the programme may be extended for longer than the initial five year pilot period.

He stated: “There are currently four cannabis products on the schedule and two more to be added to schedule one of the regulations in the coming weeks. I understand that one of the products in the schedule namely CannEpil is expected to be available in October, subsequent to the introduction of the necessary legislation.”

According to Lorraine Nolan the chief executive of HPRA, since the MCAP regulations came into force in June 2019, 34 applications have been made for cannabis-based products.

Of these four cannabis oils have been placed in schedule one of the regulations, and two dry herb products have completed the final HPRA review and are awaiting a ministerial decision. Five are currently under active review.

Nolan commented: “The first cannabis-based products are expected to be made available to Irish patients through MCAP in October 2021. Once these are accessed by Irish patients, the HPRA will receive any reports of suspected adverse events and review them for any signals of concern regarding the safety of the product.

READ MORE  Cannabis and chronic pain - what the latest research says

“The HPRA will also have a role in investigating any quality issues that may arise and coordinate any action that might be subsequently required.”

Doctors are asked to register patients who may benefit from this treatment to the HSE including the condition they are being prescribed for.

The HPRA will be monitoring patients for adverse effects over the coming weeks once the medication is available.

The MCAP programme has been criticised by patients who are still waiting for access to products despite the introduction of the scheme in 2019 under then Minister for Health, Simon Harris.

O’Conner also highlighted that 192 ministerial licenses have already been issued for 67 individuals who access medication from the Netherlands.

In July a direct funding scheme was announced to remove the need for patients to pay for these prescriptions up front and then apply for reimbursement from the Government.

Continue Reading

Advocacy

Irish politicians receive cannabis in mail to mark National Legalise Cannabis day

The letters outlined the reasons why legalising cannabis in Ireland needs to be a top priority for government officials.

Published

on

Irish: A banner advert for National Legalise cannabis day

Two hundred Irish TDs received a letter outlining the reasons for cannabis legalisation and a roll-up in the post sparking an investigation

The cannabis was sent by An Póst by leading cannabis activists to mark National Legalise Cannabis Day in Ireland. The cannabis was accompanied by a letter outlining ten reasons why cannabis should be legalised and made accessible. Cannabis activists including Cannabis Activist Alliance, ReLeaf CBD Café, and Martin Condon from the podcast Martin’s World shared images of the letters online before sending them to ministers.

Two hundred letters containing cannabis roll-ups and edibles were sent to ministers including the President of Ireland, Michael D Higgins. A further forty were sent to members of the media and senators. Mary Lou McDonald of Sinn Fein was even sent a tricolour roll-up.

In a statement online, those involved encouraged other cannabis consumers and activists to get involved in the action.

“To mark the 20th anniversary of this event the Martins World Podcast, The Cannabis Activist Alliance and the ReLeaf Cafe have teamed up to recreate this event. Cannabis containing joints will again be posted to every TD and Senator in Ireland. With the joint, we will include a letter about the campaign and 10 reasons why Cannabis prohibition should be ended (there are thousands to choose from). We encourage anyone who wants to get involved to do so. It will only cost you the price of a stamp and envelope.”

Some of the benefits listed in the letters included the creation of jobs, open access for patients and researchers, the end to the discrimination faced by patients and also the protection of minors with the introduction of regulation.

READ MORE  Five tips for coping with life after lockdown

Irish cannabis market

While the letter highlighted the reasons why cannabis should be legalised in Ireland, it also gave a stern warning about the dangers of buying cannabis from an unregulated market.

“As this product was sourced from an unregulated market, you as a consumer have very little protection. There is no guarantee that this joint contains any cannabis. If it does contain cannabis you as a consumer have no idea as to the potency of the cannabis. This makes dosing incredibly difficult and could put you at risk.”

The action has sparked an investigation by Irish authorities after scanners at the ministerial buildings failed to recognise the substance. It was reported that nearly all of the Green party received a letter along with members of Fianna Fáil and Fine Gael.

Irish ministers response

Most of the ministers have not confirmed if they have or have not received the letters. However, Cathal Crowe, a Fianna Fáil TD for Clare posted a photo of the letter on Twitter confirming he had received one.

Irish Green party councillor, Oliver Moran also received a letter and tweeted his response. “Many thanks for including me in this action—and for the prudent warning that potency and content are unknown when drugs are purchased from an underground market.”

November 5 was declared  National Legalise Cannabis Day by Independent TD, Luke Ming Flanagan back in 2001. The letters campaign was created to mark the 20th anniversary of this.

READ MORE  Cannabis legalisation may reduce rates of vaping injury, finds study

Ireland’s cannabis reform

The campaign comes amidst criticism that the Medical Cannabis Access Programme is still not functioning despite reassurances that Cannephil would be available from mid-October.

People before Profit TD for Dublin Mid-West, Gino Kenny raised the issue in the Dáil to Taoiseach, Michael Martin.

“Many families would have been very joyous during the summer when the medical cannabis access programme was to commence. But sadly, in a PQ response today, not one patient has been given access thus far. That is a huge disappointment to those families that this treatment could make life-changing benefits,” he said.

He added: “So what do you say to families that feel let down by the program and now they have to look at other treatments and probably getting no treatment at all?”

Michael Martin replied by saying that a lot of patients have been facilitated by the original ‘imported license’ but was unsure as to why patients had not availed of the MCAP. He promised to follow up with the Minister for Health which is currently Stephen Donnelly of Fianna Fáil.

Gino also announced changes to the Cannabis Regulation and Control bill that he is due to submit. It will now take place next year with a focus on production and consumption for personal use.

Image credit : Martin’sWorld

READ MORE  CBD drink maker’s NHS pledge

Irish: A banner advertising a competition

Continue Reading

Trending